A combination of mifepristone and misoprostol is the gold standard treatment for induction of labour in women with late intrauterine fetal death. This article attempts to review the current best available evidence as well as provide an insight based on the available evidence regarding the dosing regimens and safety in women with a previous caesarean section.
A combination of mifepristone and misoprostol is the gold standard treatment for induction of labour in women with late intrauterine fetal death. This article attempts to review the current best available evidence as well as provide an insight based on the available evidence regarding the dosing regimens and safety in women with a previous caesarean section.
Learning objectives
To review the pharmacokinetics, mode of action, efficacy, adverse effects, dose and route of administration of mifepristone and misoprostol.
To review the safety of misoprostol in women with previous caesarean section and other uterine scars.
Ethical issues
To identify the most effective regimen with the fewest adverse effects. To balance the desire to achieve a quick and successful induction with the risk of complications including uterine rupture in women with previous uterine scars. To provide a sympathetic approach to women who are already emotionally stressed.
Introduction
Pregnancy loss at any stage is emotionally distressing, but can be even more so at advanced gestations of more than 24 weeks when the fetus is deemed legally viable. Spontaneous labour and delivery may not occur for several weeks and therefore a clear management plan, which includes induction of labour, is necessary to reduce the time-related risk of psychological distress and sepsis (if the membranes are ruptured).
For pregnancies of less than 24 weeks, a range of safe and effective medical and rarely surgical interventions is available. However, induction of labour beyond this gestational age is often limited to the use of medical agents, of which a combination of mifepristone and misoprostol is the most popular treatment, especially in the more resourced countries. Occasionally, mechanical methods using a cervical balloon and, rarely, surgical procedures such as hysterotomy and caesarean section are used beyond this gestational age.
This article reviews the pharmacokinetics, mode of action, efficacy, adverse effects, dose and route of administration of mifepristone and misoprostol, as well as their safety in unique circumstances such as previous caesarean section.
Pharmacokinetics and mode of action
Mifepristone is a synthetic steroid with anti-progesterone activity. The pharmacokinetics of oral administration are characterised by rapid absorption and a long half-life of 25-30 hours. 1 It competitively blocks both progesterone and glucocorticoid receptors, leading to decidual necrosis, increased endogenous production of prostaglandins, increased uterine sensitivity to prostaglandins and cervical ripening so that lower doses of prostaglandins and prostaglandin analogues are required to induce delivery.
Misoprostol is a PGE 1 analogue that was originally approved for the prevention and treatment of peptic ulcers because of its antigastric acid secretory properties and its various mucosal protective properties. Oral administration is characterised by rapid absorption and higher peak but lower sustained levels compared with the higher bioavailability and sustained levels with vaginal administration. [5] [6] [7] However, vaginal absorption may be influenced by pH and amount of vaginal discharge and bleeding. Sublingual administration is characterised by rapid absorption and the highest peak levels and bioavailability because of avoidance of the first-pass metabolism by the liver. 6 Most studies 5-7 have shown that a sustained level rather than a high level is required for the onset of uterine contractions, although they have not been able to define this threshold level. Therefore vaginal administration is the cornerstone of most dosing regimens. The onset and duration of action of these agents for the most commonly used routes of administration are summarised in Table 1 . Misoprostol is cheap, easy to use and is stable at room temperature. This makes it an ideal agent for induction of labour, particularly in settings where the use of PGE 2 is not possible owing to lack of availability, facilities for storage or financial constraints.
Currently, misoprostol is marketed in the UK only as a 200 lg tablet; however, the required dosage of 50 lg or 100 lg can be obtained by cutting the tablet or by dilutional methods. 8 The local hospital pharmacist will be able to assist with this if necessary. 9 It is important to note that, although it is widely used, misoprostol is not licensed for the induction of labour.
Efficacy studies, dosing regimens and adverse effects
Although there is robust evidence demonstrating the safety and efficacy of mifepristone and misoprostol for the termination of first-and second-trimester pregnancies, [10] [11] [12] their use for the induction of labour for late fetal death (more than 24 weeks) is largely limited to observational and non-randomised controlled comparative trials.
Misoprostol-only regimens
The use of misoprostol-only regimens for the management of intrauterine death has been reviewed by Ponce de Leon and Wing. 13 The authors excluded trials with methodological errors, incomplete reporting and those with a non-randomised design; only 14 randomised controlled trials were included in the final analysis. These included trials that compared various dose regimens and routes of administration of misoprostol with other interventions and were varied in terms of the study population, dosage regimens and definition of successful treatment. For example, some studies used an induction to delivery interval of 24 hours to define success, whereas others used 48-hour or 72-hour thresholds for success. Most studies restricted success of induction to cases where misoprostol alone was used, while others included those where adjuvant treatment with oxytocin was used.
Overall, the vaginal route of administration was associated with a longer induction to delivery interval but fewer gastrointestinal adverse effects compared with oral or sublingual routes. The induction to delivery interval was reported to be significantly shorter with the administration of 600 lg vaginal misoprostol versus 400 lg. However, no formal dose-finding studies have been performed in the setting of second-or third-trimester fetal demise.
Misoprostol was as effective as vaginal PGE 2 , gemeprost or extra-amniotic PGF 2a , with fewer adverse effects. The induction to delivery interval was significantly less with misoprostol than with the use of oxytocin, especially for gestations less than 28 weeks. The results of the review are derived from relatively small trials investigating pregnancy termination for intrauterine fetal death in the second trimester (13-28 weeks) . Both the sensitivity of the uterus to prostaglandins and the strength of contractions that are required to achieve a clinical effect increase with gestational age. 14 PGE 2 is widely used for induction of labour in women with a live fetus. Although there are studies comparing it with misoprostol in induction of labour, there are none comparing both drugs in women with late intrauterine fetal death. The RCOG's Green-top Guideline Late Intrauterine Fetal Death and Stillbirth 9 recommends the use of misoprostol over PGE 2 because it has an equivalent safety and efficacy profile but with lower costs.
There is no robust evidence assessing the safety and efficacy of misoprostol or of suitable alternatives for the management of late intrauterine fetal death, especially in the third trimester (more than 28 weeks).
Combination of mifepristone and misoprostol
The combination of mifepristone and misoprostol in the management of intrauterine fetal death is one of the major advances in modern clinical practice, with safety and efficacy reported by numerous observational and non-randomised controlled trials. [15] [16] [17] [18] [19] However, certain issues remain unresolved regarding its use. These include the optimum dose of both mifepristone and misoprostol, the best route of administration of misoprostol and the most effective interval between the administration of both drugs.
Published studies report a mean induction to delivery interval of 10-19 hours with the use of the misoprostol-only regimen and a shorter induction to delivery interval of 7-10 hours with the use of the combination mifepristonemisoprostol regimen. [20] [21] [22] [23] [24] [25] For example, Wagaarachchi et al., 15 in the largest case series to date (n=96) using a combination regimen for the management of late intrauterine fetal death, reported a mean induction to delivery interval of 8.5 hours, which is shorter than published studies using misoprostol-only. The induction to delivery interval was also shorter with increasing gestation and 95.8% of the women delivered within 48 hours.
In contrast, the only non-randomised controlled study 16 comparing women with intrauterine fetal death at 21-42 weeks treated with a combination regimen (n=48) with those treated with misoprostol alone (n=82), reported a significantly shorter induction to delivery interval only in women with earlier gestations (21-25 weeks) with the use of the combination regimen. Paradoxically, the induction to delivery interval with increasing gestations in the misoprostol-only group was shorter than the corresponding induction to delivery interval with the combined regimen. The discrepancy in these findings may be related to the dose of misoprostol used in the two groups; the combination regimen group was prescribed a dose of 25 lg 4-hourly, which is significantly less than that used in the misoprostol-only group who received a median dose of 100 lg per administration. The dose is also significantly lower than that used in other published reports and possibly explains why the reported median induction to delivery interval of 12.8 hours in this study is the highest among all published studies using the combination regimen. Nevertheless, the total dose of misoprostol needed was lower in the group who were pretreated with mifepristone. Cumulative percentages of women delivering within 12, 24, 48 and 72 hours from the the start of misoprostol administration in both groups were similar and by 48 hours, 92.7% and 93.5% of the women had delivered in the misoprostol-only and mifepristone-misoprostol groups, respectively.
In a study comparing two regimens of misoprostol in 47 cases of late intrauterine fetal death managed using the combination regimen, 17 the use of 800 lg vaginal misoprostol followed by a maximum of four additional doses of 400 lg oral misoprostol at 4-hourly intervals resulted in a shorter induction to delivery interval (median 7 versus 10.2 hours). This was compared with a second regimen of up to five doses of 50 lg vaginal misoprostol at 3-hourly intervals. A higher incidence of gastrointestinal adverse effects was noted with the vaginal/oral regimen. Four women with previous caesarean section were included in the study.
Most current guidelines 26 recommend a time interval of 36-48 hours between administration of mifepristone and misoprostol on the basis of mechanistic studies showing peak sensitivity of the uterine muscle to PG and PG analogues following such an interval. 27 This is also backed by robust evidence from studies on termination of pregnancy in the first and second trimesters, where a reduced mifepristonemisoprostol interval has been shown to result in reduced efficacy and the need for higher total doses of misoprostol. However, because of the nature of the diagnosis of intrauterine fetal death, and its associated emotional distress, women and their caregivers are often keen for a quick resolution and delivery. Therefore the interval is often shortened or even abolished completely as in many of the observational trials reported previously. With lack of comparative data, it is difficult to evaluate the impact of such practice on efficacy and safety, especially the remote risk of uterine rupture resulting from the subsequent need to use higher doses of misoprostol.
In summary, while 200 mg mifepristone is to be given orally, the vaginal route may be the gold standard route of administration for misoprostol, with oral or sublingual administration reserved for those women at risk of malabsorption related to vaginal discharge or bleeding or for women who need a repeat regimen for failed induction. The recommended dose of misoprostol is 50 lg given 6-hourly up to a maximum of five doses per course. 9, 28 Very high success rates and an acceptable induction to delivery interval can be achieved with a dose regimen as low as 25 lg administered vaginally at 4-hour intervals. 28 The need for pretreatment with mifepristone and the ideal mifepristone-misoprostol interval is yet to be clearly defined for women with late intrauterine fetal death.
Women with previous caesarean section and other uterine scars
With increasing caesarean section rates, a rise in the number of women with a scarred uterus who experience an intrauterine fetal death becomes inevitable. Caution is advised in these women because of the potentially greater risk of uterine rupture with the use of prostaglandins 29 and oxytocics.
Berghella et al. 30 reviewed all published trials on the termination of pregnancy at 16-28 weeks in women who had had one or more prior caesarean delivery. They reported two uterine ruptures (incidence 0.43%, 95% confidence interval [CI] 0.08-1.67%) out of 461 women with one prior low transverse caesarean birth and no ruptures in 46 women with ª 2014 Royal College of Obstetricians and Gynaecologists two prior caesarean births following the use of misoprostol for medical induction. Three further cases of uterine rupture in women with one previous section were reported as case reports. With the inclusion of these three cases the uterine rupture rate increased to 1.1%. Three of the ruptures occurred at 26 weeks, two of which were in women given oxytocin in addition to their initial misoprostol dosing. Both cases that occurred before 26 weeks were associated with total misoprostol dosing of more than 1000 lg. The reported incidence is comparable with the uterine scar rupture rate of 0.4-0.5% with spontaneous-onset vaginal birth after caesarean section and is much lower than the incidence of rupture in 79 women (3.9%) who were induced with agents such as PGE 2 , oxytocin or both. 31 Initial case series reports in the last decade of the 20 th century estimated an unacceptably high (up to 5.6%) incidence of uterine rupture with the use of misoprostol for induction of labour with a live fetus in women with previous caesarean section. 32, 33 A large population-based cohort study reported a uterine rupture rate of 2.45% for prostaglandin inductions compared with 0.5% for spontaneous labour in women with one previous caesarean birth. 34 The study lacked data specific to misoprostol use and included the use of all prostaglandin inductions in its risk assessment. A population-based study that evaluated the rupture risk of women undergoing induction of labour for a live fetus reported rupture rates of 0.8% and 1.1%, respectively, with the use of misoprostol and oxytocin. 35 Although there are no specific large-scale data available for women with intrauterine fetal death, the risk of uterine rupture is unlikely to be different from that published for induction and augmentation of labour in women with a live fetus. There are insufficient data to stratify this risk based on the number (one versus multiple), location (upper versus lower uterine segment) and nature (caesarean versus non-caesarean) of scars. The majority of published guidelines contraindicate (or advise extreme caution with) the use of misoprostol in women with uterine scars. 9, 36 Therefore, where the use is routine, care should be taken to administer a dose of less than 50 lg vaginally at 4-hourly intervals for a maximum of five doses. Oral or sublingual administration, prolonged induction (more than five doses) and a repeat regimen for failed induction should be discouraged. The optimum mifepristone-misoprostol interval of 36-48 hours should be observed to reduce the dosage of misoprostol required and therefore the risk of uterine rupture. An intrauterine fetal death is a disaster; a uterine rupture in the background of an intrauterine fetal death is a catastrophe.
Retained placenta or placental fragments is another complication of the use of misoprostol in the management of late intrauterine fetal death. This is seen more frequently with second-trimester inductions for intrauterine fetal death than with those in the third trimester.
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International guidelines
The World Health Organization adopted the recommendations of an expert group on misoprostol 38 in its guideline on induction of labour which was published in 2011. 36 These were ratified by the International Federation of Gynecology and Obstetrics (FIGO) and incorporated into its misoprostol dosage guideline published in 2012. 39 The updated guideline recommends 100 lg misoprostol vaginally 6-hourly (maximum of four doses) for a gestational age of 18-26 weeks and 25 lg vaginally 6-hourly or 25 lg orally 2-hourly (maximum not specified for both routes) for late intrauterine fetal death. Caution is advised in women with a previous scar for a gestational age of 18-26 weeks, whereas the use of misoprostol is contraindicated in women with late intrauterine fetal death.
The RCOG Green-top Guideline 9 recommends adjustment of misoprostol dose according to gestational age (100 lg 6-hourly before a gestational age of 26 weeks and 25-50 lg 4-hourly for a gestational age of 27 weeks or more. This is similar to the recommendation endorsed by the National Institute for Health and Care Excellence in 2008. 40 The use of misoprostol at the recommended doses is considered safe in women with one previous caesarean section.
Clearly, these major international guidelines differ on the dose and regimens to be used for different gestational ages as well as for women with a previous uterine scar. The confusion is as a result of limited data available for evidence-based practice, especially as higher doses of misoprostol seem to achieve shorter induction to delivery interval. This review attempts to reconcile the differences and present a balanced common sense approach ( Table 2) .
Use of mechanical (non-pharmacological) methods of induction in women with a previous uterine scar A standard Foley catheter or a proprietary Cook cervical ripening balloon are the most commonly used mechanical methods of cervical ripening for the induction of labour. 41 Because of the risks associated with pharmacological agents, the use of mechanical methods is on the rise in women with a previous caesarean section and other uterine scars. 42 A 2012 Cochrane review that analysed 71 published randomised controlled trials (n=9722 women) reported similar vaginal delivery rates with lower risk of hyperstimulation with the use of mechanical methods than with other pharmacological methods for induction of labour. 41 Subgroup analysis of women with caesarean section or other uterine scars was not reported.
An observational trial of induction of labour in 1083 women (term induction of labour, n=969) with a Bishop score of less than 6, using a 26F Foley catheter combined with extra-amniotic saline infusion, reported an overall vaginal delivery rate of 73.9% and a complication rate of less than 10%. 43 The complications included acute transient febrile reaction (3%), non-reassuring cardiotocograph (2%), vaginal bleeding (1.8%) and unbearable pain which necessitated removal of the catheter (1.7%). The vaginal birth rate for the 97 women with one previous caesarean section was 80.4%.
A retrospective chart review of outcomes for 2479 women undergoing vaginal birth after caesarean reported very high vaginal birth rates for women undergoing spontaneous labour (78%, n=1807) and amniotomy with or without oxytocin (77.9%, n=417) compared with those following the use of a Foley catheter (55.7%, P<0.001, n=255). 44 The rates of uterine rupture were comparable in the three groups (1.1 versus 1.2 versus 1.6%, respectively).
However, this study compared induction with a Foley catheter versus spontaneous labour with or without artificial rupture of membranes with or without oxytocin. There are no studies comparing the use of Foley catheter with prostaglandin for induction of labour in women with a previous caesarean section. Also there are no studies on the use of mechanical methods of induction in women with intrauterine fetal death.
Conclusion
Late intrauterine fetal death (after 24 weeks of gestation) is a relatively rare diagnosis and given the associated emotional distress, both for the woman and her care provider, it is no surprise that there is a lack of well-designed large-scale randomised controlled trials to guide its management. A combination of mifepristone and misoprostol is safe, effective, practical and inexpensive, although there is no robust evidence on the most ideal treatment regimen. Women with a previous scar should be counselled about the increased risk of uterine rupture irrespective of the method used for inducing labour.
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